CN116286415B - Brevibacterium citricum strain and application thereof - Google Patents
Brevibacterium citricum strain and application thereof Download PDFInfo
- Publication number
- CN116286415B CN116286415B CN202310572001.2A CN202310572001A CN116286415B CN 116286415 B CN116286415 B CN 116286415B CN 202310572001 A CN202310572001 A CN 202310572001A CN 116286415 B CN116286415 B CN 116286415B
- Authority
- CN
- China
- Prior art keywords
- aging
- expression
- genes
- cell
- rhodosporidium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000186146 Brevibacterium Species 0.000 title claims description 6
- 241000223252 Rhodotorula Species 0.000 claims abstract description 21
- 230000004663 cell proliferation Effects 0.000 claims abstract description 10
- 230000001737 promoting effect Effects 0.000 claims abstract description 10
- 230000008591 skin barrier function Effects 0.000 claims abstract description 9
- 241000306752 Salmoneus Species 0.000 claims abstract description 8
- 238000004321 preservation Methods 0.000 claims abstract description 8
- 239000002537 cosmetic Substances 0.000 claims abstract description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 48
- 210000004027 cell Anatomy 0.000 claims description 44
- 230000014509 gene expression Effects 0.000 claims description 38
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 35
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 34
- 210000002744 extracellular matrix Anatomy 0.000 claims description 34
- 239000006228 supernatant Substances 0.000 claims description 23
- 238000006731 degradation reaction Methods 0.000 claims description 21
- 239000000047 product Substances 0.000 claims description 21
- 210000003491 skin Anatomy 0.000 claims description 21
- 230000003712 anti-aging effect Effects 0.000 claims description 19
- 230000015556 catabolic process Effects 0.000 claims description 18
- 230000006907 apoptotic process Effects 0.000 claims description 17
- 239000006166 lysate Substances 0.000 claims description 17
- 230000008439 repair process Effects 0.000 claims description 15
- 239000003102 growth factor Substances 0.000 claims description 14
- 210000002510 keratinocyte Anatomy 0.000 claims description 12
- 230000004888 barrier function Effects 0.000 claims description 10
- 230000015572 biosynthetic process Effects 0.000 claims description 10
- 238000003786 synthesis reaction Methods 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 9
- 230000010261 cell growth Effects 0.000 claims description 8
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 claims description 7
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 6
- 230000012010 growth Effects 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 230000035755 proliferation Effects 0.000 claims description 6
- 230000003827 upregulation Effects 0.000 claims description 6
- 229920001817 Agar Polymers 0.000 claims description 5
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 5
- 102100028071 Fibroblast growth factor 7 Human genes 0.000 claims description 5
- 101001060261 Homo sapiens Fibroblast growth factor 7 Proteins 0.000 claims description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 5
- 239000008272 agar Substances 0.000 claims description 5
- 238000012300 Sequence Analysis Methods 0.000 claims description 4
- 210000002615 epidermis Anatomy 0.000 claims description 4
- 241000233866 Fungi Species 0.000 claims description 3
- 241000209140 Triticum Species 0.000 claims description 3
- 235000021307 Triticum Nutrition 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 238000007254 oxidation reaction Methods 0.000 claims description 3
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 claims description 2
- 101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 claims description 2
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 claims description 2
- 241000319304 [Brevibacterium] flavum Species 0.000 claims description 2
- 230000003828 downregulation Effects 0.000 claims description 2
- 230000003647 oxidation Effects 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 claims 2
- 241000223651 Aureobasidium Species 0.000 claims 1
- 102100035290 Fibroblast growth factor 13 Human genes 0.000 claims 1
- 230000007969 cellular immunity Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 239000002054 inoculum Substances 0.000 claims 1
- 239000007858 starting material Substances 0.000 claims 1
- 238000002474 experimental method Methods 0.000 abstract description 11
- 230000032683 aging Effects 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 4
- 244000005700 microbiome Species 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract description 2
- 238000000034 method Methods 0.000 description 12
- 239000003963 antioxidant agent Substances 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 8
- 230000003078 antioxidant effect Effects 0.000 description 8
- 230000002222 downregulating effect Effects 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 241001052560 Thallis Species 0.000 description 6
- 210000002950 fibroblast Anatomy 0.000 description 6
- 238000011529 RT qPCR Methods 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 239000013592 cell lysate Substances 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 4
- 206010051246 Photodermatosis Diseases 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 description 4
- 239000001569 carbon dioxide Substances 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 230000008845 photoaging Effects 0.000 description 4
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 3
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 238000002247 constant time method Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000003973 Fibroblast growth factor 21 Human genes 0.000 description 2
- 108090000376 Fibroblast growth factor 21 Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241000736262 Microbiota Species 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000032677 cell aging Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 239000002955 immunomodulating agent Substances 0.000 description 2
- 230000002584 immunomodulator Effects 0.000 description 2
- 229940121354 immunomodulator Drugs 0.000 description 2
- 230000004957 immunoregulator effect Effects 0.000 description 2
- 230000000415 inactivating effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000002068 microbial inoculum Substances 0.000 description 2
- 230000004792 oxidative damage Effects 0.000 description 2
- 239000006041 probiotic Substances 0.000 description 2
- 235000018291 probiotics Nutrition 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000009759 skin aging Effects 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 210000003046 sporozoite Anatomy 0.000 description 2
- 101150084750 1 gene Proteins 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 102100027308 Apoptosis regulator BAX Human genes 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000009089 Collagen Type XIII Human genes 0.000 description 1
- 108010073180 Collagen Type XIII Proteins 0.000 description 1
- 229920000832 Cutin Polymers 0.000 description 1
- 102000005927 Cysteine Proteases Human genes 0.000 description 1
- 108010005843 Cysteine Proteases Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 description 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 238000003794 Gram staining Methods 0.000 description 1
- 108010020382 Hepatocyte Nuclear Factor 1-alpha Proteins 0.000 description 1
- 108091023242 Internal transcribed spacer Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000003840 Opioid Receptors Human genes 0.000 description 1
- 108090000137 Opioid Receptors Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- 241000235342 Saccharomycetes Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- 102000011990 Sirtuin Human genes 0.000 description 1
- 108050002485 Sirtuin Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 235000019714 Triticale Nutrition 0.000 description 1
- 101000998548 Yersinia ruckeri Alkaline proteinase inhibitor Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000004900 autophagic degradation Effects 0.000 description 1
- 108700000707 bcl-2-Associated X Proteins 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000001808 exosome Anatomy 0.000 description 1
- -1 exosomes Substances 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000003958 fumigation Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000007236 host immunity Effects 0.000 description 1
- 229940124644 immune regulator Drugs 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000003475 metalloproteinase inhibitor Substances 0.000 description 1
- BFBPISPWJZMWJN-UHFFFAOYSA-N methyl 2-[(7-hydroxy-3,7-dimethyloctylidene)amino]benzoate Chemical compound COC(=O)C1=CC=CC=C1N=CCC(C)CCCC(C)(C)O BFBPISPWJZMWJN-UHFFFAOYSA-N 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000006654 negative regulation of apoptotic process Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 244000039328 opportunistic pathogen Species 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000004215 spore Anatomy 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 241000228158 x Triticosecale Species 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/14—Fungi; Culture media therefor
- C12N1/16—Yeasts; Culture media therefor
- C12N1/165—Yeast isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/14—Yeasts or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/14—Yeasts or derivatives thereof
- A23L33/145—Extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/064—Saccharomycetales, e.g. baker's yeast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9728—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/14—Fungi; Culture media therefor
- C12N1/16—Yeasts; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/302—Foods, ingredients or supplements having a functional effect on health having a modulating effect on age
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/218—Yeast extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/76—Yeasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/645—Fungi ; Processes using fungi
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Nutrition Science (AREA)
- Dermatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Alternative & Traditional Medicine (AREA)
- Birds (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Medical Informatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses a rhodosporidium aurantiacum and application thereof, and relates to the technical field of microorganisms. The invention discloses a rhodosporidium citricolaSporobolomyces salmoneus) The strain is named SEUNEU-122 and is preserved in China center for type culture collection (China center for type culture Collection) at 9 and 14 of 2022, and the preservation number is CCTCC No. M20221431. Experiments show that SEUNEU-122 has effects of promoting cell proliferation, repairing skin barrier, and resisting aging, and can be used for preparing medicines, cosmetics, etc.
Description
Technical Field
The invention belongs to the technical field of microorganisms, and particularly relates to a rhodosporidium aurantiacum and application thereof.
Background
Skin aging is divided into two types, internal and external: one is that the natural aging of the skin is caused by the aging and the decline of the metabolism of cells in the body; the other is skin aging due to external environmental factors. Of these, photoaging is the most predominant form of extrinsic aging of skin, and the primary cause of photoaging of skin is ultraviolet radiation. Photoaging causes abnormal expression of ROS, production of MMPs, COX-2, etc., and causes inflammation to occur, while cell proliferation decreases, apoptosis increases, and extracellular matrix components (collagen, elastin, glycosaminoglycan, etc.) significantly decrease with aging of skin.
In the research of aging mechanism, it is found that autophagy can delay organ function degradation, and can provide protection for photoaged damaged skin by removing damaged proteins and lipids in cells irradiated by UV. In addition, it has been demonstrated that reducing apoptosis, reducing cell inflammation, increasing extracellular matrix synthesis and reducing degradation thereof, improving antioxidant capacity of cells, etc. can slow down skin cell aging.
Skin microorganisms are important members of the skin micro-ecosystem, and recent studies have demonstrated that the skin microbiota regulates the expression of various innate factors, and that skin resident bacteria are not only passive resident bacteria; they actively participate in host immunity through the intact skin barrier. The innate immune system of the skin in combination with the skin microbiota is a barrier of the human body against pathogenic microorganisms and opportunistic pathogens. Skin has self-renewal ability, and skin microorganism can decompose phospholipids, sterols, and keratin to make skin cells absorb and promote cell growth, delay aging, and reduce wrinkle. Therefore, the probiotics related product developed by utilizing the microecology technology has important practical significance.
Disclosure of Invention
In view of the above, the invention aims to provide a Sporobora citri and application thereof.
One object of the present invention is to provide a Sporobora citriSporobolomyces salmoneus) The strain is named SEUNEU-122 and is preserved in China center for type culture collection (China center for type culture Collection) at 9 and 14 of 2022, and the preservation number is CCTCC No. M20221431.
Preferably, the strain is sampled from the epidermis of black wheat with Qingdao flatness, and is identified as Brevibacterium flavum according to the sequence analysis of fungus ITS genes, and named as SEUNEU-122;
the orange red spore throwing yeast is in a long ellipse shape under a microscope; growing on a wort agar plate to form a smooth, opaque and sticky flat colony with red color and neat edge; haze growth in malt juice liquid medium.
The invention aims to provide the application of the rhodosporidium aurantiacum in preparing a product for improving skin conditions; wherein the improving the skin condition comprises at least one of promoting cell proliferation, repairing skin barrier, and anti-aging.
In some embodiments, the promoting keratinocyte proliferation is promoting proliferation of skin keratinocytes.
The invention takes HaCaT keratinocytes as a test object to study the effect of promoting cell proliferation of Sporobora aurantiaca. The result shows that the rhodosporidium aurantiacum can promote repair of HaCaT keratinocyte injury caused by SDS, improve the cell proliferation rate, and promote the proliferation rate to be 20.38% -23.23%.
In some embodiments, the repairing the skin barrier comprises restoring cell viability and/or upregulating expression of a barrier repair-related gene; the barrier repair related gene isOVOL1。
According to the invention, haCaT keratinocytes are taken as a test object, and the SDS damage repair capability of the Sporobusta aurantiaca is researched, so that the results show that the Sporobusta aurantiaca can repair cell damage caused by SDS, improve the cell proliferation rate and up-regulate the expression of barrier repair related genes of non-damaged cells.
In some embodiments, the anti-aging comprises at least one of the following expressions:
a) The anti-aging comprises up-regulating expression of extracellular matrix synthesis-related genes comprisingSPTSSA、TIMP1、LN、MKXAndCOL13A1at least one of (a) and (b);
b) The anti-aging includes up-regulating cell antioxidant-associated genesSIRT-1Is expressed by (a);
c) The anti-aging includes up-regulating genes related to cellular immune modulatorsMORIs expressed by (a);
d) The anti-aging comprises up-regulating expression of a cell growth factor related gene comprisingFGF1、FGF2、FGF7、FGF21Andin HGFAt least one of (a) and (b);
e) The anti-aging comprises up-regulating and inhibiting the expression of apoptosis-related gene BCL-2;
f) The anti-aging comprises down-regulating the expression of apoptosis-related genes comprisingBAXAnd/orCaspase-3；
g) The anti-aging comprises down-regulating the expression of genes related to extracellular matrix degradation, wherein the genes related to extracellular matrix degradation compriseMMP1And/orMMP3。
In order to explore the anti-aging effect of the Sporobusta aurantiaca, the invention detects the index related to cell aging, wherein the index comprises at least one of extracellular matrix synthesis, cell oxidation resistance, cell immunoregulatory factors, cell growth factors, apoptosis and extracellular matrix degradation.
The invention takes HaCaT keratinocytes as a test object to study the influence of Sporobora aurantiaca on genes related to synthesis and degradation of extracellular matrix of the HaCaT keratinocytes. The results show that the Sporobora aurantiaca can up-regulate the genes related to the synthesis of extracellular matrixTIMP1Promoting synthesis of extracellular matrix; down-regulating degradation of extracellular matrix related genesMMP1Inhibit degradation of extracellular matrix.
The invention takes HFF cells as a test object to study the influence of the Sporobora aurantiaca on genes related to the synthesis of extracellular matrix of HFF cells and genes related to degradation. The results show that the Sporobora aurantiaca can up-regulate the genes related to the synthesis of extracellular matrixSPTSSA、LN、MKXAndCOL13A1promoting synthesis of extracellular matrix; down-regulating degradation of extracellular matrix related genesMMP3Inhibit degradation of extracellular matrix.
The invention takes HFF fibroblasts as a test object to study the influence of the Sporobora citrifolia on the expression of the HFF fibroblasts antioxidant related genes. The result shows that the rhodosporidium aurantiacum can up-regulate the related gene for resisting oxidizationSIRT- 1Is of (2)Thereby enhancing the antioxidant capacity of the cells.
The invention takes HFF fibroblasts as a test object to study the influence of the Sporobora citrifolia on the expression of the HFF fibroblast immunoregulatory factor related genes. The result shows that the rhodosporidium aurantiacum can up-regulate the gene related to the immune regulatorMOREnhancing the immunomodulatory ability of the cell.
The invention takes HFF fibroblast as a test object to study the influence of the Sporobora citrifolia on the expression of the HFF fibroblast cell growth factor related gene. The results show that the Sporobora aurantiaca can up-regulate the cell growth factor related genesFGF1、FGF2、FGF7、FGF21、HGFEnhancing the immunomodulatory ability of the cell.
The invention takes HFF cells as a test object to study the influence of the Sporobora aurantiaca on the inhibition of apoptosis of HFF. The result shows that the rhodosporidium aurantiacum can up-regulate and inhibit apoptosis related genesBCL-2Is effective in inhibiting apoptosis.
The invention takes HFF cells as a test object to study the influence of the Sporobora aurantiaca on the apoptosis of the HFF cells. The result shows that the rhodosporidium aurantiacum can down regulate the apoptosis related genesBAXAndCaspase-3is effective in inhibiting apoptosis.
It is a further object of the present invention to provide a product for improving skin conditions made from a material comprising the above-mentioned Sporobora citrifolia yeast.
Further, the product is a pharmaceutical or cosmetic product.
Still further, the product also includes a flora comprising Sporobora citri.
Still further, the product comprises a microbial inoculum made of a bacterial strain containing Sporobora aurantiaca and a lysate thereof, a supernatant fluid, or a microbial inoculum made of a bacterial population containing Sporobora aurantiaca.
Further, the product is in the form of at least one of cream, emulsion, oil, water, gel, powder and freeze-drying.
It is an object of the present invention to provide a method for improving the condition of the skin comprising the use of the slave product according to the invention. The application method comprises smearing, external application, fumigation or injection.
The invention discloses a rhodosporidium citricolaSporobolomyces salmoneus) SEUNEU-122, which is a Sporobusta aurantiaca with a preservation number of CCTCC No. M20221431. Experiments show that the rhodosporidium aurantium provided by the invention has the functions of promoting keratinocyte proliferation, improving skin barrier, resisting aging, enhancing skin antibacterial capability, reducing hair loss, whitening and removing aged cutin, and can be used for preparing medicines, cosmetics and the like.
Description of biological preservation
Orange red sporozoite yeastSporobolomyces salmoneus) SEUNEU-122 was deposited at China center for type culture collection (CCTCC for short, address: eight channel 299 No. of Wuchang district of Wuhan, university of Wuhan, post code 430072) at 9 and 14 days 2022, and its deposit number was CCTCC No. M20221431.
Detailed Description
The invention provides a rhodosporidium aurantiacum and application thereof. Those skilled in the art can, with the benefit of this disclosure, suitably modify the process parameters to achieve this. It is expressly noted that all such similar substitutions and modifications will be apparent to those skilled in the art, and are deemed to be included in the present invention. While the methods and applications of this invention have been described in terms of preferred embodiments, it will be apparent to those skilled in the relevant art that the invention can be practiced and practiced with modification and alteration and combination of the methods and applications herein without departing from the spirit and scope of the invention.
The rhodosporidium aurantialba strain SEUNEU-122 is derived from the black wheat epidermis with the Qingdao flatness, and is identified as the rhodosporidium aurantialba strain SEUNEU-122 through fungus ITS gene sequence analysisSporobolomyces salmoneus). The strain is in a long ellipse shape under a microscope; growing on a wort agar plate to form a smooth, opaque and sticky flat colony with red color and neat edge; the growth is carried out in the malt juice liquid medium in a turbid way, and the optimal growth temperature is 20 ℃.
Orange red sporozoite yeastSporobolomyces salmoneus) SEUNEU-122, accession number: china center for type culture Collection, address: in the Jiuqiu No. 299 university of Wuhan, hubei province, the date of preservation: and 2022, 9 and 14 days, wherein the preservation number is CCTCC NO: M20221431.
The invention provides a rhodosporidium aurantiacum SEUNEU-122 in the application or product of the invention, which is in the form of living or dead or batch sterilized, or in the form of lysate and/or extract, or in the form of bacterial product, or in the form of supernatant or derivative, preferably selected from: metabolites, metabolic biological products, exosomes, probiotics, cell walls and components thereof, extracellular polysaccharides and compounds containing immunogenic components, preferably selected from the group consisting of: inactivating the supernatant and the thallus lysate.
The test materials adopted in the invention are all common commercial products and can be purchased commercially, and the invention is further described below by combining examples:
EXAMPLE 1 isolation of SEUNEU-122
Samples were taken on triticale epidermis. After the sample is properly treated, shaking and uniformly mixing the sample in normal saline, streaking the supernatant on a wort agar plate, culturing the sample at the constant temperature of 20 ℃ for 24-30 hours, and then picking red colonies, repeatedly inoculating and screening the red colonies until a uniform single colony is obtained, and the colony is named as SEUNEU-122.
Gram staining microscopy: the strain is in a long ellipse shape under a microscope; growing on a wort agar plate to form a smooth, opaque and sticky flat colony with red color and neat edge; the growth is carried out in the malt juice liquid medium in a turbid way, and the optimal growth temperature is 20 ℃.
EXAMPLE 2 nucleic acid identification of SEUNEU-122
1. Fungal ITS gene sequence analysis
Single colony is selected and placed in malt juice liquid culture medium, after culturing overnight at 20 ℃, the single colony is centrifuged at 12000r/min for 1min to collect thalli, and the operation is carried out according to the step of extracting the yeast genome DNA kit. The primers adopt saccharomycete universal primers ITS1 and ITS4, the PCR amplification system is a 15 mu l system, and the primers are pre-denatured for 5min at 95 ℃;95 ℃,30 s,60 ℃,30 s,72 ℃,60 s,35 cycles; extending at 72℃for 7min.
2. Results
The PCR product sequencing result is compared with the published standard sequence in GenBank (BLASTN) to obtain the SEUNEU-122 strain which is Brevibacterium citricolaSporobolomyces salmoneus）。
Example 3SEUNEU-122 promoting SDS-induced repair of HaCaT injury in human immortalized keratinocytes
1. Preparation of SEUNEU-122 supernatant
Selecting single colony of Brevibacterium citricola SEUNEU-122 in malt wort liquid medium, shake culturing at 20deg.C for 24-30 hr, detecting with enzyme-labeled instrument, diluting with PBS, and adjusting OD 600 Centrifugation at 12000r/min for 2min at 121℃for 30min under 0.28Mpa, and filtering with 0.22 μm filter membrane to obtain inactivated supernatant.
2. Promoting HaCaT cell repair experiments
Inoculation of HaCaT cells (5×10) 4 cells/well) to 96-well plates, cultured overnight to cell attachment. 50. Mu.g/ml SDS was prepared, 100. Mu.l of each well was added thereto, and the mixture was incubated in a 5% carbon dioxide incubator at 37℃for 8 hours. Each well was incubated with 5% (V/V) supernatant (control was replaced with equal volume of PBS) for 24h. To each well, 10. Mu.l of CCK-8 solution was added, and the mixture was incubated for 4 hours, and absorbance A at 450nm was measured.
Cell proliferation rate calculation formula and results are shown in the following table:
as shown in the above table, both the SEUNEU-122 supernatant and the cell lysate can repair HaCaT keratinocyte injury caused by SDS, improve the cell proliferation rate and promote the proliferation rate to be 20.38% -23.23%.
Example 4SEUNEU-122 promotion of HaCaT Barrier maintenance-related Gene expression experiments
1. Preparation of SEUNEU-122 supernatant and thallus lysate
Picking up Brevibacterium citricola SEUNEU-122 listColony is cultured in malt juice culture medium at 20 deg.c for 24-30 hr, enzyme label instrument for detection and PBS dilution to regulate OD 600 Centrifugation at 12000r/min for 2min at 121℃for 30min under 0.28Mpa, and filtering with 0.22 μm filter membrane to obtain inactivated supernatant. The method comprises the steps of washing the centrifugally precipitated thalli twice by PBS, adding liquid nitrogen, grinding and crushing, collecting crushed bacterial mud, re-suspending the crushed bacterial mud to the volume of the centrifugally precipitated thalli by PBS, crushing the crushed thalli by ultrasonic waves for 20min, and inactivating the crushed thalli at 121 ℃ for 30min and 0.28Mpa to obtain a thalli lysate.
2. Promote HaCaT barrier repair related gene expression experiment
Inoculated human immortalized keratinocyte HaCaT (2 ml/well, 5X 10 contained therein) 5 Cells) to 6-well plates, 5% carbon dioxide incubator at 37 ℃ overnight until cells adhere. Respectively adding 5% (V/V) supernatant and 10% (V/V) thallus lysate (the control group respectively replaces supernatant and thallus lysate with equal volume PBS), culturing for 24 hr, adding lysate, extracting total RNA of cells, detecting RNA concentration and purity, and reverse transcribing into cDNA to obtain final productGAPDHAs reference gene, real-time qPCR detection was usedOVOL1Expression of the genes. The control group (relative gene expression fold f=1) was treated with PBS added in equal volume, using 2 -ΔΔCT The F value of each sample was calculated by the method.
The formula: f=2 -ΔΔCT Wherein:
△CT experiment =CT Experiment -CT Internal reference (experiment) ；
△CT Control =CT Control -CT Internal reference (control) ；
△△CT=△CT Experiment -△CT Control 。
Supernatant up-regulating barrier repair geneOVOL1. The results are shown in the following table:
thallus lysate up-regulating barrier repairing geneOVOL1. The results are shown in the following table:
in vitro cell experiments show that the supernatant and the thallus lysate of the Sporobora aurantiaca SEUNEU-122 have the OVO-like transcription factor 1 genes related to up-regulation skin barrier repairOVOL1The expression function, the up-regulation multiple of the gene expression quantity is 1.38-3.91. SEUNEU-122 has been shown to have an effect of promoting skin barrier repair.
Example 5SEUNEU-122 Regulation of photoaging HaCaT extracellular matrix/degradation of extracellular matrix-related Gene expression experiments
1. Preparation of SEUNEU-122 supernatant and thallus lysate
The preparation is described in example 4.
2. HaCaT cell preparation and ultraviolet injury
HaCaT cells were digested and then subjected to 0.5 mL/well (containing 2X 10 cells) 5 Cells) were inoculated into 24-well plates and incubated overnight at 37℃in a 5% carbon dioxide incubator. The total dose of cells in the well was 2J/cm 2 Is damaged by ultraviolet UVB irradiation.
3. SEUNEU-122 addition
The supernatant 5% (V/V) and the cell lysate 10% (V/V) were added to the stimulated HaCaT cells, respectively (control group replaced supernatant/cell lysate with equal volume of PBS, respectively). Each group was incubated overnight at 37℃in parallel with 3.
4. qPCR method for detecting relative expression fold of extracellular matrix/extracellular matrix degradation related genes
Removing culture medium from above cells, adding lysate, extracting total RNA of cells, detecting RNA concentration and purity, and reverse transcribing into cDNAGAPDHAs reference genes, real-time qPCR was used to detect extracellular matrix-related genesTIMP1And degradation of extracellular matrix-related genesMMP1. Relative expression fold f=1, using 2 for control group genes -ΔΔCT The F value of each sample was calculated by the method.
Supernatant down-regulating extracellular matrix degradation related genesMMP1. The results are shown in the following table:
up-regulating extracellular matrix gene by thallus lysateTIMP1. The results are shown in the following table:
in vitro cell experiments show that the rhodosporidium aurantiacum SEUNEU-122 has matrix metalloproteinase family genes related to down-regulating extracellular matrix degradationMMP1Gene expression effect, gene relative expression multiple 0.33-0.58; tissue metalloprotease inhibitor 1 gene with function of up-regulating HaCaT extracellular matrixTIMP1The gene expression function, the relative expression multiple of the gene is 1.14-1.36.
EXAMPLE 6SEUNEU-122 Regulation of oxidative damage HFF extracellular matrix/apoptosis/cellular antioxidant/cellular immune modulator/cytokine related Gene expression experiments
1. Preparation of SEUNEU-122 supernatant and thallus lysate
The preparation is described in example 4.
2. HFF cell preparation and H 2 O 2 Induced oxidative damage
After digestion of HFF cells in DMEM culture, the cells were subjected to digestion at 0.5 ml/well (containing 2X 10 cells) 5 Cells) were inoculated into 24-well plates and incubated overnight at 37℃in a 5% carbon dioxide incubator. H was added to each well at a final concentration of 200. Mu.M 2 O 2 Stimulation was performed and the mixture was allowed to stand at 37℃for 1 hour.
3. SEUNEU-122 addition
Supernatant 5% (V/V) and cell lysate 10% (V/V) were added to stimulated HFF cells, respectively (control group replaced supernatant/cell lysate with equal volume of PBS, respectively). Each group was incubated overnight at 37℃in parallel with 3.
4. qPCR method for detecting relative expression fold of extracellular matrix/apoptosis/cell antioxidant/cell immune regulator/cell growth factor related genes
Removing culture medium from above cells, adding lysate, and extractingDetecting the concentration and purity of total RNA of cells, and then reversely transcribing the total RNA into cDNA toGAPDHAs reference genes, real-time qPCR was used to detect extracellular matrix-related genesLN、MKX、SPTSSAAndCOL13A1inhibiting apoptosis-related genesBCL-2Cell antioxidant related geneSIRT-1Cell immunomodulator related genesMORCell growth factorFGF1、FGF2、FGF7、FGF21、HGFGenes related to extracellular matrix degradationMMP3Apoptosis-related genesCaspase-3AndBAX. Relative expression fold f=1, using 2 for control group genes -ΔΔCT The F value of each sample was calculated by the method.
Supernatant up-regulates extracellular matrix-related genesMKXAndSPTSSA，gene inhibiting apoptosisBCL-2Cell antioxidant related geneSIRT-1Cell immunomodulator related genesMORCell growth factorFGF2、FGF7AndFGF21the method comprises the steps of carrying out a first treatment on the surface of the Down-regulating extracellular matrix degradation related genesMMP3Apoptosis-related genesCaspase-3 andBAXthe results are shown in the following table:
up-regulating extracellular matrix related genes by thallus lysateLN、SPTSSAAndCOL13A1inhibiting apoptosis-related genesBCL-2Antioxidant related genesSIRT-1Immunomodulatory factor-related genesMORCell growth factor FGF1,FGF2、FGF7、FGF21AndHGF. The results are shown in the following table:
in vitro cell experiments show that the rhodosporidium aurantiacum SEUNEU-122 has the function of up-regulating the laminin related to the HFF extracellular matrixLNMo Huoke protein geneMKX、Serine palmitoyltransferaseSPTSSAAnd type XIII collagen alpha 1 chain geneCOL13A1Inhibiting apoptosis-related B lymphocytoma-2 geneBCL-2Antioxidant-related Sirtuins protein family genesSIRT-1Immune modulator-related beta-endorphin receptor genesMORAnd a fibroblast growth factor related to the cell growth factorFGF1Fibroblast growth factorFGF2Keratinocyte growth factorFGF7Fibroblast growth factorFGF21And hepatocyte growth factorHGFThe expression function, the relative expression multiple of the genes is 1.06-2.44; matrix metalloproteinase family genes associated with downregulation of extracellular matrix degradationMMP3Apoptosis-related BCL2-Associated X protein genesBAXAnd cysteine protease family genesCaspase-3The relative expression times of genes are 0.56-0.87.
The foregoing is merely a preferred embodiment of the present invention and it should be noted that modifications and adaptations to those skilled in the art may be made without departing from the principles of the present invention, which are intended to be comprehended within the scope of the present invention.
Claims (5)
1. Brevibacterium citricum strainSporobolomyces salmoneus) The strain is named SEUNEU-122 and is preserved in China center for type culture collection (China center for type culture collection) at 9 and 14 days of 2022, and the preservation number is Balanomyces aureobasidium for orange red with the preservation number of M20221431; the Sporobora aurantialba is sampled from the black wheat epidermis of Qingdao flatness, and identified by fungus ITS gene sequence analysis, is named as SEUNEU-122; the orange red spore throwing yeast is in a long ellipse shape under a microscope; growing on a wort agar plate to form a smooth, opaque and sticky flat colony with red color and neat edge; haze growth in malt juice liquid medium.
2. Use of the rhodosporidium orange of claim 1 for the preparation of a product for improving skin conditions; wherein the improving skin condition is at least one of promoting cell proliferation, repairing skin barrier, and anti-aging;
the promotion of cell proliferation is promotion of skin keratinocyte proliferation;
the repair of the skin barrier is the up-regulation of the expression of a gene associated with barrier repair; the barrier repair related gene isOVOL1；
The anti-aging is at least one of the following expressions:
a) The anti-aging is the up-regulation of the expression of genes related to extracellular matrix synthesis, which areSPTSSA、TIMP1、LN、MKXAndCOL13A1at least one of (a) and (b);
b) The anti-aging is up-regulated cell oxidation related geneSIRT-1Is expressed by (a);
c) The anti-aging is up-regulating cell immunity regulating factor related geneMORIs expressed by (a);
d) The anti-aging is the up-regulation of the expression of a cell growth factor related gene which isFGF1、FGF2、FGF7、FGF21Andin HGFAt least one of (a) and (b);
e) The anti-aging is the up-regulation and inhibition of the expression of apoptosis related gene BCL-2;
f) The anti-aging is the down-regulation of the expression of apoptosis-related genes, which areBAXAnd/orCaspase-3；
g) The anti-aging is to down regulate the expression of extracellular matrix degradation related genes, wherein the extracellular matrix degradation related genes areMMP1And/orMMP3。
3. A product for improving skin conditions, characterized by being made from a material comprising the rhodosporidium orange yeast of claim 1 or 2.
4. A product according to claim 3, wherein the product is a pharmaceutical or cosmetic product.
5. The product according to claim 3 or 4, wherein the starting material for the rhodosporidium aurantiacum in the product is at least one of the following:
(1) The flora and/or inoculant of Brevibacterium flavum;
(2) Inactivated supernatant and thallus lysate of the rhodosporidium aurantiacum.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310572001.2A CN116286415B (en) | 2023-05-22 | 2023-05-22 | Brevibacterium citricum strain and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310572001.2A CN116286415B (en) | 2023-05-22 | 2023-05-22 | Brevibacterium citricum strain and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116286415A CN116286415A (en) | 2023-06-23 |
| CN116286415B true CN116286415B (en) | 2023-08-11 |
Family
ID=86827310
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310572001.2A Active CN116286415B (en) | 2023-05-22 | 2023-05-22 | Brevibacterium citricum strain and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116286415B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104245938A (en) * | 2011-06-10 | 2014-12-24 | 淡马锡生命科学研究院有限公司 | Genetic manipulation and expression systems for pucciniomycotina and us tilaginom ycotina subphyla |
| CN114058559A (en) * | 2022-01-17 | 2022-02-18 | 山东锦鲤生物工程有限公司 | Staphylococcus epidermidis and application thereof |
| CN115197856A (en) * | 2022-09-08 | 2022-10-18 | 山东锦鲤生物工程有限公司 | Cordyceps militaris strain and application thereof |
-
2023
- 2023-05-22 CN CN202310572001.2A patent/CN116286415B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104245938A (en) * | 2011-06-10 | 2014-12-24 | 淡马锡生命科学研究院有限公司 | Genetic manipulation and expression systems for pucciniomycotina and us tilaginom ycotina subphyla |
| CN114058559A (en) * | 2022-01-17 | 2022-02-18 | 山东锦鲤生物工程有限公司 | Staphylococcus epidermidis and application thereof |
| CN115197856A (en) * | 2022-09-08 | 2022-10-18 | 山东锦鲤生物工程有限公司 | Cordyceps militaris strain and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| Feng-Yan Bai.Reclassification of the Sporobolomyces roseus and Sporidiobolus pararoseus complexes, with the description of Sporobolomyces phaffii sp. nov.Int J Syst Evol Microbiol.2002,第2309-2314页. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116286415A (en) | 2023-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN115261273A (en) | Lactobacillus jensenii and application thereof | |
| CN115094011A (en) | Lactobacillus gasseri and application thereof | |
| CN116333939A (en) | Bifidobacterium breve and application thereof | |
| CN116286415B (en) | Brevibacterium citricum strain and application thereof | |
| CN115044519B (en) | Lactobacillus amyloliquefaciens and application thereof | |
| CN115058373B (en) | Sake lactobacillus and application thereof | |
| CN116555070A (en) | Bifidobacterium bifidum and application thereof | |
| CN115678814A (en) | Lactobacillus salivarius and application thereof | |
| CN115505550A (en) | Lactobacillus paracasei and application thereof | |
| CN115584333A (en) | Lactobacillus reuteri and application thereof | |
| CN115369047A (en) | Kluyveromyces marxianus strain and application thereof | |
| CN115197856A (en) | Cordyceps militaris strain and application thereof | |
| CN116445306B (en) | Schizosaccharomyces pombe and its application in improving skin condition | |
| CN116355770B (en) | Debaryomyces hansenii and application thereof | |
| CN115927119B (en) | Bacillus simplex and application thereof | |
| CN115678807B (en) | Bifidobacterium longum and application thereof | |
| CN115820476B (en) | Lactobacillus delbrueckii and application thereof | |
| CN116555055A (en) | Candida parapsilosis strain and application thereof | |
| CN116478875A (en) | Bacillus cereus and application thereof | |
| CN115710553A (en) | Candida tropicalis and application thereof | |
| CN115287204B (en) | Kluyveromyces marxianus strain and application thereof | |
| CN115927024A (en) | Saccharomyces cerevisiae and application thereof | |
| CN115725428A (en) | Candida parapsilosis strain and application thereof | |
| CN116218716A (en) | Bifidobacterium pseudocatenulatum and application thereof | |
| CN115747086A (en) | Pichia kluyveri and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |